Wedbush initiated coverage on shares of Ascendis Pharma AS (NASDAQ:ASND) in a research note issued to investors on Monday morning. The firm issued an outperform rating and a $34.00 target price on the stock.
A number of other brokerages have also recently commented on ASND. TheStreet upgraded shares of Ascendis Pharma AS from a sell rating to a hold rating in a report on Tuesday, September 6th. Leerink Swann restated a buy rating on shares of Ascendis Pharma AS in a report on Friday, September 2nd. Finally, Zacks Investment Research upgraded shares of Ascendis Pharma AS from a hold rating to a buy rating and set a $17.00 target price on the stock in a report on Monday, August 15th.
Ascendis Pharma AS (NASDAQ:ASND) opened at 20.31 on Monday. The stock has a 50 day moving average of $18.87 and a 200 day moving average of $16.13. The stock’s market cap is $511.67 million. Ascendis Pharma AS has a 1-year low of $11.92 and a 1-year high of $21.70.
Ascendis Pharma AS (NASDAQ:ASND) last announced its earnings results on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.10. Equities analysts anticipate that Ascendis Pharma AS will post ($3.14) EPS for the current fiscal year.
Ascendis Pharma AS Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related companies with MarketBeat.com's FREE daily email newsletter.